SEC Tracker
Get the app

Redwoods Acquisition GRML

Redwoods Acquisition Q3 FY23: net income $290K; diluted EPS −$0.01

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Redwoods Acquisition reported for Q3 FY23, the quarter ended Sep 30, 2023, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income$290KNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Diluted EPS−$0.01No year-earlier figure tagged10-Q income statement, on EDGAR
  3. Cash and cash equivalents$146KNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  4. Cash from operations−$127KNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Redwoods Acquisition files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Cue Biopharma CUE public float $52M, Jun 30, 2025
  2. Avalo Therapeutics AVTX public float $54M, Jun 30, 2025
  3. Fitlife Brands FTLF public float $51M, Jun 30, 2025
  4. Immucell ICCC public float $51M, Jun 30, 2025
  5. iBio IBIO public float $58M, Dec 31, 2025